These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20020236)

  • 1. Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.
    Imasawa M; Tsumura T; Sekine A; Kikuchi T; Iijima H
    Jpn J Ophthalmol; 2009 Nov; 53(6):588-592. PubMed ID: 20020236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
    Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
    Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
    Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
    Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
    Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
    Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy.
    Yodoi Y; Tsujikawa A; Kameda T; Otani A; Tamura H; Mandai M; Yoshimura N
    Am J Ophthalmol; 2007 Jun; 143(6):984-994. PubMed ID: 17336913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
    Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
    Kang HM; Kim YM; Koh HJ
    Am J Ophthalmol; 2013 Mar; 155(3):438-447.e1. PubMed ID: 23218705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy.
    Lai TY; Lam CP; Luk FO; Chan RP; Chan WM; Liu DT; Lam DS
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):91-5. PubMed ID: 20148658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Yamashita A; Shiraga F; Shiragami C; Shirakata Y; Fujiwara A
    Am J Ophthalmol; 2013 Jan; 155(1):96-102.e1. PubMed ID: 22995028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
    Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humphrey perimetry as a predictor of visual improvement after photodynamic therapy.
    Imasawa M; Tsumura T; Kikuchi T; Sekine A; Iijima H
    Jpn J Ophthalmol; 2009 May; 53(3):281-2. PubMed ID: 19484454
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
    Mori R; Yuzawa M; Lee Z; Haruyama M; Akaza E
    Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1233-9. PubMed ID: 20352440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
    Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
    Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.
    Chan WM; Liu DT; Lai TY; Li H; Tong JP; Lam DS
    Clin Exp Ophthalmol; 2005 Dec; 33(6):611-8. PubMed ID: 16402954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ; Yu HG
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
    Lai TY; Lee GK; Luk FO; Lam DS
    Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.
    Silva RM; Figueira J; Cachulo ML; Duarte L; Faria de Abreu JR; Cunha-Vaz JG
    Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):973-9. PubMed ID: 15864616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.